Literature DB >> 16716

Beta-2 adrenoceptor blocking activity of penbutolol and propranolol at very low doses.

R D Kulkarni, L M DaSilva, N L Chabria, D R Chadha.   

Abstract

The relative potency of penbutolol, a new beta adrenergic receptor blocking agent, was compared with propranolol by a four-point assay on healthy male subjects. A dose-response relationship to intravenous doses of propranolol in the microgram range was obtained during a steady state of infusion of epinephrine. Two subjects underwent the entire assay according to the Latin square design and four others each underwent one schedule of design on different days. The potency of penbutolol thus assessed was consistent with reported results. This study emphasizes the importance of intersubject variation and differential receptor sensitivity in individuals. The use of epinephrine as a beta receptor adrenergic agonist for evaluation of selective beta adrenergic receptor blocking activities is discussed.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 16716     DOI: 10.1002/cpt1977216685

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  3 in total

1.  Intrinsic sympathomimetic activity of penbutolol.

Authors:  G Nyberg; C Wilhelmsson; A Vedin
Journal:  Eur J Clin Pharmacol       Date:  1979       Impact factor: 2.953

2.  A standard approach to compiling clinical pharmacokinetic data.

Authors:  L B Sheiner; L Z Benet; L A Pagliaro
Journal:  J Pharmacokinet Biopharm       Date:  1981-02

3.  Penbutolol: a preliminary review of its pharmacological properties and therapeutic efficacy in hypertension and angina pectoris.

Authors:  R C Heel; R N Brogden; T M Speight; G S Avery
Journal:  Drugs       Date:  1981-07       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.